Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Disease area: Airway diseases

Abstract

Eicosanoids are mediators of arachidonic acid pathway. Induced sputum (IS) is a non-invasive material from the lower airways; its sampling is well standardized. Advantage of exhaled breath condensate (EBC) is shorter collection time and low protein content, but this is compromised by extreme dilution and inter-individual variation. Both matrices have been introduced for assessment of inflammatory mediators in asthma.
We compared eicosanoids concentration in IS and EBC samples collected according to the current guidelines and estimated redistribution of eicosanoids and their metabolites as a result of sample processing.
EBC was collected from asthmatics using Jaeger ECO Screen I; IS according to the most recent ERS Task Force recommendations. The same validated quantitative mass spectrometry was used for both matrices ecosanoids‘ measurements. Random IS samples were split to test enzymatic inhibition during solubilisation.
We quantified 29 eicosanoids, including major prostaglandins, leukotrienes, and their metabolites. Average concentration of eicosanoids was 82 [1-400] times lower in EBC than in IS. IS differed form EBC by higher HETE and undetectable LTC4. Conversion of LTB4 into 5-oxo-LTB4 and increase of tetranor-PGEM was observed during IS solubilisation, non-physiological pH prevented these redistributions only partially.
Although processing of IS shifts eicosanoid profile toward metabolites, significant amounts of mediators are present within detection levels of common immunoassays. A strict adherence to the IS collection protocols is recommended to avoid a pre-analytical bias.
In collaboration with U-BIOPRED within the Innovative Medicine Initiative

Rating:

Share or cite this content

Citations should be made in the following way:
M. Sanak, L. Mastalerz, A. Gielicz, B. Sokolowska, N. Celejewska-Wójcik, A. Szczeklik (Kracow, Poland). Targeted eicosanoid lipidomics of induced sputum as compared to exhaled breath condensate in asthmatics. Eur Respir J 2011; 38: Suppl. 55, 4789

Member's Comments

No comment yet.

Related content which might interest you: Inflammatory mediators in exhaled breath condensate, induced sputum and saliva Source: Eur Respir J 2004; 24: Suppl. 48, 678s Year: 2004 Validation of eicosanoid measurements in exhaled breath condensate Source: Eur Respir J 2002; 20: Suppl. 38, 422s Year: 2002 Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation Source: Eur Respir J 2004; 24: 1011-1017 Year: 2004 Content of nitric oxide in the exhaled breath condensate, induced sputum and BAL in asthma and COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 369s Year: 2006 Ozone-induced airway inflammation and its attenuation by corticosteroids are detectable in sputum samples but not in exhaled breath condensate Source: Eur Respir J 2004; 24: Suppl. 48, 577s Year: 2004 Cytokines in exhaled breath condensate of patients with asthma Source: Annual Congress 2008 - Inflammatory biomarkers Year: 2008 Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma Source: Eur Respir J 2002; 20: 1393-1398 Year: 2002 Cystenil-leukotrienes as markers of airway inflammation in exhaled breath condensate of asthmatic children Source: Eur Respir J 2002; 20: Suppl. 38, 412s Year: 2002 Metabolomics applied to exhaled breath condensate in asthmatic children treated with inhaled steroids Source: Virtual Congress 2020 – Novel mechanisms and management of paediatric asthma Year: 2020 Cysteinyl leukotrienes in urine and exhaled breath condensate in asthmatics and COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 59s Year: 2005 Endogenous and exogenous metabolites in exhaled breath condensate in asthma Source: Annual Congress 2012 - Exhaled biomarkers in airway diseases Year: 2012 Exercise-induced changes in concentrations of cysteinyl-leukotrienes in exhaled breath condensate Source: Eur Respir J 2004; 24: Suppl. 48, 680s Year: 2004 Prediction of CF exacerbations by FeNO and non-invasive inflammatory markers in exhaled breath condensate Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation Year: 2008 Increased 8-isoprostane in the exhaled breath condensate of down patients Source: Eur Respir J 2004; 24: Suppl. 48, 556s Year: 2004 Nasal lavage cysteinyl-leukotrienes correlate with exhaled breath condensate in children Source: Eur Respir J 2006; 28: Suppl. 50, 259s Year: 2006 Correlation of LTB4 with α-amylase in exhaled breath condensate Source: Eur Respir J 2005; 26: Suppl. 49, 372s Year: 2005 Leukotrienes in exhaled breath condensate of children with asthma Source: Eur Respir J 2001; 18: Suppl. 33, 39s Year: 2001 The biomarkers of atopy in exhaled breath condensate in patients with bronchial asthma Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases Year: 2010 8-isoprostane and cys-leukotrienes in exhaled breath condensate (EBC) of children with asthma exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 142s Year: 2002